Laura Mauri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Mauri has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Robert W. Yeh
Beth Israel Deaconess Medical Center, Boston, MA, USA
2 shared publicationsAjay J. Kirtane
Division of Cardiology, Columbia University/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA
1 shared publicationAlice K. Jacobs
Boston University School of Medicine, Boston, MA (A.K.J.).
1 shared publicationDean J. Kereiakes
The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education, Cincinnati, OH (D.J.K)
1 shared publication- Dean J. Kereiakes
Christ Hospital Heart and Vascular Center/The Carl and Edyth Lindner Center for Research and Education, Christ Hospital, Cincinnati, Ohio
1 shared publication - Dean J. Kereiakes
The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, Ohio 45219, USA
1 shared publication
Latest Publications
- 1 August 2018
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 11 (8) , e005308
Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women
Background: Women may derive differential benefit from prolonged DAPT (dual antiplatelet therapy) after coronary stenting than men. We assessed whether the risks/benefits of prolonged DAPT differ between women and men. Methods and Results: The DAPT study was a randomized double-blind, placebo-controlled trial comparing continued thienopyridine versus placebo beyond 12 months after coronary stenting. We compared rates of myocardial infarction, stent thrombosis, major adverse cardiovascular and cerebrovascular events, and bleeding by sex and randomized treatment. Of 11 648 patients, women (N=2925) were older, with higher prevalence of diabetes mellitus and lower rates of acute coronary syndrome than men. At 12 to 30 months, women had similar adjusted ischemic and bleeding events as men. The effects of continued thienopyridine therapy did not differ significantly by sex for stent thrombosis (women: hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.22–1.36; men: HR, 0.26; 95% CI, 0.15–0.44; interaction P =0.17), myocardial infarction (women: HR, 0.75; 95% CI, 0.50–1.14; men: HR, 0.46; 95% CI, 0.36–0.60; interaction P =0.052), major adverse cardiovascular and cerebrovascular events (women: HR, 0.87; 95% CI, 0.62–1.22; men: HR, 0.70; 95% CI, 0.58–0.85; interaction P =0.26), and bleeding (women: HR, 1.45; 95% CI, 0.88–2.40; men: HR, 1.78; 95% CI, 1.28–2.49; interaction P =0.50). Conclusions: Women had similar late risks of ischemia and bleeding as men after coronary stent procedures. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00977938.
- 1 August 2018
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 11 (8) , e005308
Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women
Background: Women may derive differential benefit from prolonged DAPT (dual antiplatelet therapy) after coronary stenting than men. We assessed whether the risks/benefits of prolonged DAPT differ between women and men. Methods and Results: The DAPT study was a randomized double-blind, placebo-controlled trial comparing continued thienopyridine versus placebo beyond 12 months after coronary stenting. We compared rates of myocardial infarction, stent thrombosis, major adverse cardiovascular and cerebrovascular events, and bleeding by sex and randomized treatment. Of 11 648 patients, women (N=2925) were older, with higher prevalence of diabetes mellitus and lower rates of acute coronary syndrome than men. At 12 to 30 months, women had similar adjusted ischemic and bleeding events as men. The effects of continued thienopyridine therapy did not differ significantly by sex for stent thrombosis (women: hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.22–1.36; men: HR, 0.26; 95% CI, 0.15–0.44; interaction P =0.17), myocardial infarction (women: HR, 0.75; 95% CI, 0.50–1.14; men: HR, 0.46; 95% CI, 0.36–0.60; interaction P =0.052), major adverse cardiovascular and cerebrovascular events (women: HR, 0.87; 95% CI, 0.62–1.22; men: HR, 0.70; 95% CI, 0.58–0.85; interaction P =0.26), and bleeding (women: HR, 1.45; 95% CI, 0.88–2.40; men: HR, 1.78; 95% CI, 1.28–2.49; interaction P =0.50). Conclusions: Women had similar late risks of ischemia and bleeding as men after coronary stent procedures. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00977938.